ArticleExperimental brain research2026
Knockdown of RNF128 attenuated Parkinson's-induced mitochondrial dysfunction in neurons by stabilizing the SIRT1 protein.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Mitochondrial dysfunction is closely related to the pathogenesis of Parkinson’s disease (PD). Studies have shown that ubiquitination plays a crucial role in regulating mitochondrial dysfunction. As a ubiquitin ligase, RNF128 may influence mitochondrial function by modulating its ubiquitination activity. This study aimed to investigate the specific effect and mechanism of RNF128 on PD-induced mitochondrial dysfunction in neurons. Animal and cellular models of PD were established for experimental investigation by intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice and treatment of SH-SY5Y cells with 1-methyl-4-phenylpyridinium (MPP+). Motor function was evaluated via the rotarod test and pole climbing test; pathological brain tissue damage was detected via H&E staining; mitochondrial function was detected via MitoSOX Red staining, JC-1 staining, and ATP content determination. The binding of RNF128 and SIRT1 was detected via coimmunoprecipitation, and the expression levels of related proteins were detected via Western blotting and immunofluorescence. The result shows that RNF128 is highly expressed in PD. Knocking down RNF128 improves MPTP-induced motor dysfunction, increases the number of TH-positive neurons, and attenuates brain tissue damage in PD mice. At the cellular level, knocking down RNF128 led to reduced mitochondrial ROS levels and increased mitochondrial membrane potential and ATP levels, thereby ameliorating MPP+-induced mitochondrial dysfunction in neuronal cells. In terms of molecular mechanisms, the expression of SIRT1 is downregulated in PD, and RNF128 interacts with SIRT1 to increase the ubiquitination and degradation of SIRT1. Knocking down SIRT1 partially reverses the improvement in mitochondrial function achieved by knocking down RNF128. Overall, knocking down RNF128 improves mitochondrial dysfunction by increasing SIRT1 expression, thereby alleviating neuronal injury in PD.
Indexed as
Identifiers
41865322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.